California Public Employees Retirement System Has $19.64 Million Stake in Haemonetics Co. (NYSE:HAE)

California Public Employees Retirement System lifted its stake in shares of Haemonetics Co. (NYSE:HAE) by 36.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 229,717 shares of the medical instruments supplier’s stock after buying an additional 61,935 shares during the quarter. California Public Employees Retirement System’s holdings in Haemonetics were worth $19,643,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Haemonetics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock worth $482,017,000 after purchasing an additional 27,146 shares in the last quarter. Westfield Capital Management Co. LP lifted its stake in Haemonetics by 37.0% during the 3rd quarter. Westfield Capital Management Co. LP now owns 559,963 shares of the medical instruments supplier’s stock valued at $50,161,000 after acquiring an additional 151,144 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Haemonetics by 6.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 525,793 shares of the medical instruments supplier’s stock valued at $47,101,000 after acquiring an additional 33,294 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Haemonetics by 50.0% during the 3rd quarter. Victory Capital Management Inc. now owns 357,303 shares of the medical instruments supplier’s stock valued at $32,007,000 after acquiring an additional 119,072 shares in the last quarter. Finally, Eagle Asset Management Inc. lifted its stake in Haemonetics by 2.6% during the 3rd quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier’s stock valued at $24,065,000 after acquiring an additional 6,828 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Trading Up 3.8 %

Shares of HAE opened at $90.99 on Monday. The business has a 50-day moving average of $80.40 and a 200 day moving average of $82.55. Haemonetics Co. has a fifty-two week low of $70.74 and a fifty-two week high of $95.26. The firm has a market cap of $4.62 billion, a P/E ratio of 36.99, a price-to-earnings-growth ratio of 2.15 and a beta of 0.36. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The company had revenue of $336.20 million during the quarter, compared to analyst estimates of $320.84 million. During the same quarter last year, the firm posted $0.85 EPS. The firm’s revenue for the quarter was up 10.1% on a year-over-year basis. As a group, research analysts forecast that Haemonetics Co. will post 3.95 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Barrington Research restated an “outperform” rating and set a $105.00 price objective on shares of Haemonetics in a research note on Friday, April 12th. TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. Finally, StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.